Neuren Pharmaceuticals Limited (NURPF)
- Previous Close
0.00 - Open
8.05 - Bid 7.36 x 21500
- Ask 7.95 x 40000
- Day's Range
8.05 - 8.05 - 52 Week Range
6.60 - 14.25 - Volume
100 - Avg. Volume
483 - Market Cap (intraday)
1.074B - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
11.63 - EPS (TTM)
0.70 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.
www.neurenpharma.comRecent News: NURPF
View MorePerformance Overview: NURPF
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NURPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NURPF
View MoreValuation Measures
Market Cap
1.07B
Enterprise Value
931.84M
Trailing P/E
11.66
Forward P/E
74.63
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.77
Price/Book (mrq)
4.43
Enterprise Value/Revenue
6.82
Enterprise Value/EBITDA
8.29
Financial Highlights
Profitability and Income Statement
Profit Margin
65.51%
Return on Assets (ttm)
34.05%
Return on Equity (ttm)
49.92%
Revenue (ttm)
216.83M
Net Income Avi to Common (ttm)
142.04M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
222.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.25M